Non-Hodgkin's lymphoma: pathogenesis, clinical presentation, and treatment.
Cohen
K
K
Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center, Partners AIDS Research Center, Harvard Medical School, USA.
Scadden
D T
DT
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D000998:Antiviral Agents / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002140:California; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004854:Herpesvirus 4, Human / Q000302:isolation & purification; D019288:Herpesvirus 8, Human / Q000302:isolation & purification; D018451:Homosexuality, Male; D006801:Humans; D007262:Infusions, Intravenous; D016393:Lymphoma, B-Cell / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D016399:Lymphoma, T-Cell / Q000473:pathology; D008297:Male; D011379:Prognosis; D012042:Registries; D014750:Vincristine / Q000627:therapeutic use
D000998:Antiviral Agents; D001761:Bleomycin; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide